Cognition Therapeutics receives a US patent for Alzheimer’s drug


Cognition Therapeutics has received a US patent for a drug to fight Alzheimer’s disease. The patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer’s disease. 

Cognition Therapeutics has pioneered the use of disease-relevant screening technology that closely models the pathology of neurodegenerative diseases and novel, high-quality central nervous system-biased chemical libraries. These platforms can predict behavioural efficacy of candidate drugs in Alzheimer’s models. The US National Stage Application: No. 13/263,162, titled “Inhibitors of Cognitive Decline” was filed on October 6, 2011.

Cognitive Therapeutics chief executive officer Hank Safferstein says, “The allowance of this patent demonstrates the strength of Cognition Therapeutics’s intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer’s disease.”